Acadia Pharmaceuticals Archives

Acadia Pharmaceuticals broadens Rett syndrome treatment flexibility with DAYBUE STIX rollout in the United States

By Pallavi Madhiraju on April 8, 2026 Pharma & Biotech

Acadia Pharmaceuticals has launched DAYBUE STIX for Rett syndrome in the U.S. Read what this means for adoption, tolerability, and market strategy.

Acadia expands DAYBUE delivery formats for Rett syndrome with powder-based STIX

By Venkatesh B on December 13, 2025 Pharma & Biotech

Acadia Pharmaceuticals has announced U.S. Food and Drug Administration approval for DAYBUE STIX (trofinetide) for oral solution, a new powder-based formulation of its existing drug DAYBUE used in the treatment of Rett syndrome. The approval covers use in adult and pediatric patients two years and older and is based on bioequivalence data, not new clinical […]